Another study found that anlotinib was associated with PD-L1 inhibitors in a retrospective cohort of 32 patients with pretreated metastatic STS, achieving an ORR of 34.4% and median PFS of 7.6 months. This evidence concerns the gene CD274 and telomere syndrome.